The review shows that people with MO due to BRVO benefit from treatment with anti-VEGF with an increased chance of improved vision at six and 12 months when compared with no treatment, laser or ...

Introduction Calcium dobesilate (CaD) has been used in the treatment of diabetic retinopathy (DR) due to its potential in protecting against retinal vascular damage. However, there is limited evidence ...

X-linked retinoschisis is a recessive disease characterized by progressive macular degeneration and vision loss due to pathogenic variation in RS1. We administered a single subretinal injection of an ...

Investigators analyzed a large real-world dataset of more than 800,000 individual letter readings to determine if small shifts in visual acuity and contrast sensitivity constitute clinically ...

Assessment of visual function by testing for visual acuity, dark adaptation, contrast sensitivity and evaluation of retinal sensitivity by microperimetry can indicate different stages of disease ...

Although anti-vascular endothelial growth factor drugs have revolutionized the treatment of neovascular age-related macular degeneration (wet AMD), preventing eyes from converting from dry to wet AMD ...

BACKGROUND/AIMS The advantages of logMAR acuity data over the Snellen fraction are well known, and yet existing logMAR charts have not been adopted into routine ophthalmic clinical use. As this may be ...

Despite intravitreal anti–vascular endothelial growth factor (VEGF) therapy being the standard of care for neovascular age-related macular degeneration (nAMD), long-term visual decline remains common, ...

Please provide your email address to receive an email when new articles are posted on . If approved, privosegtor would become the first neuroprotective therapy for optic neuropathies. The PIONEER 1 ...

Sheila Irvine, one of the patients who received the implant at Moorfields hospital in the UK. A wireless retinal implant has been shown to restore vision in patients with geographic atrophy (GA), a ...

FDA grants Priority Review to idebenone for Leber Hereditary Optic Neuropathy (LHON), a disease for which there are no existing approved treatments in the U.S.; action date of February 28, 2026 PARMA, ...

Objective To validate a self-administered Home Early Treatment Diabetic Retinopathy Study (H-ETDRS) visual acuity (VA) test and to assess its accuracy in detecting VA decline in patients with retinal ...